SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that the company has expanded the European Union (EU) label indication of its Bladder EpiCheck® test. Bladder EpiCheck detects DNA methylation patterns in urine that are associated with urothelial cancer.
Go to the inbox of the email
address you just used to sign up.
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “[email protected]”.
Click on the link inside the
email and you’re good to go.